A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

Clinical trial NCT07503353 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07503353
Sponsor: Sheba Medical Center
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B Cell Malignancies Acute Lymphobkastic Leukemia Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)

Start date: 2026-06-01
Primary completion: 2029-06-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.